With Faster Effects, Vivus Hopes For Quicker Market Penetration For ED Drug Stendra
This article was originally published in The Pink Sheet Daily
Dosing instructions to take Stendra (avanafil) 30 minutes before sexual activity give the Vivus drug a shot at the crowded marketplace. With the potential approval of the obesity therapy Qnexa coming up, Vivus could be an attractive take-over target.
You may also be interested in...
Stendra Gets Its 15 Minutes, With New FDA-Approved ED Claim
Auxilium’s erectile dysfunction drug avanafil was approved by FDA for its ability to work after 15 minutes, a new claim that Auxilium expects will help to differentiate Stendra in a competitive market.
Deals Of The Week: Value Surprise!
Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen
Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.